WESTMINSTER, CA / ACCESSWIRE / May 17, 2022 / BioLargo, Inc. (OTCQB:BLGO), a developer of cleantech technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Thursday May 19, 2022, at 1:00 pm Pacific Time / 4:00 pm Eastern Time. The event, which will be open to the public, will be held to review the company's financial results for the three months ended March 31, 2022, discuss recent milestones and upcoming projects, and conduct a question-and-answer session.
To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio video software.
To participate in the live webcast and teleconference:
| Webcast Link: | |
Teleconference Domestic: | 888-506-0062 |
Teleconference International: Participant Access Code: | 973-528-0011 784818 |
To watch or listen to a replay of the webcast or teleconference:
Webcast Replay Expiration: | Friday, May 19, 2023 |
Teleconference Replay Expiration: | Thursday, June 02, 2022 |
Teleconference Replay Domestic: | 877-481-4010 |
Teleconference Replay International: | 919-882-2331 |
Replay Passcode: | 45648 |
The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo's website at www.biolargo.com/investor-relations.
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc.